Cargando…
Development of vaccine formulations: past, present, and future
The current situation, heavily influenced by the ongoing pandemic, puts vaccines back into the spotlight. However, the conventional and traditional vaccines present disadvantages, particularly related to immunogenicity, stability, and storage of the final product. Often, such products require the ma...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889058/ https://www.ncbi.nlm.nih.gov/pubmed/33598818 http://dx.doi.org/10.1007/s13346-021-00924-7 |
_version_ | 1783652236109283328 |
---|---|
author | D’Amico, Carmine Fontana, Flavia Cheng, Ruoyu Santos, Hélder A. |
author_facet | D’Amico, Carmine Fontana, Flavia Cheng, Ruoyu Santos, Hélder A. |
author_sort | D’Amico, Carmine |
collection | PubMed |
description | The current situation, heavily influenced by the ongoing pandemic, puts vaccines back into the spotlight. However, the conventional and traditional vaccines present disadvantages, particularly related to immunogenicity, stability, and storage of the final product. Often, such products require the maintenance of a “cold chain,” impacting the costs, the availability, and the distribution of vaccines. Here, after a recall of the mode of action of vaccines and the types of vaccines currently available, we analyze the past, present, and future of vaccine formulation. The past focuses on conventional formulations, the present discusses the use of nanoparticles for vaccine delivery and as adjuvants, while the future presents microneedle patches as alternative formulation and administration route. Finally, we compare the advantages and disadvantages of injectable solutions, nanovaccines, and microneedles in terms of efficacy, stability, and patient-friendly design. Different approaches to vaccine formulation development, the conventional vaccine formulations from the past, the current development of lipid nanoparticles as vaccines, and the near future microneedles formulations are discussed in this review. [Image: see text] |
format | Online Article Text |
id | pubmed-7889058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-78890582021-02-18 Development of vaccine formulations: past, present, and future D’Amico, Carmine Fontana, Flavia Cheng, Ruoyu Santos, Hélder A. Drug Deliv Transl Res Original Article The current situation, heavily influenced by the ongoing pandemic, puts vaccines back into the spotlight. However, the conventional and traditional vaccines present disadvantages, particularly related to immunogenicity, stability, and storage of the final product. Often, such products require the maintenance of a “cold chain,” impacting the costs, the availability, and the distribution of vaccines. Here, after a recall of the mode of action of vaccines and the types of vaccines currently available, we analyze the past, present, and future of vaccine formulation. The past focuses on conventional formulations, the present discusses the use of nanoparticles for vaccine delivery and as adjuvants, while the future presents microneedle patches as alternative formulation and administration route. Finally, we compare the advantages and disadvantages of injectable solutions, nanovaccines, and microneedles in terms of efficacy, stability, and patient-friendly design. Different approaches to vaccine formulation development, the conventional vaccine formulations from the past, the current development of lipid nanoparticles as vaccines, and the near future microneedles formulations are discussed in this review. [Image: see text] Springer US 2021-02-17 2021 /pmc/articles/PMC7889058/ /pubmed/33598818 http://dx.doi.org/10.1007/s13346-021-00924-7 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article D’Amico, Carmine Fontana, Flavia Cheng, Ruoyu Santos, Hélder A. Development of vaccine formulations: past, present, and future |
title | Development of vaccine formulations: past, present, and future |
title_full | Development of vaccine formulations: past, present, and future |
title_fullStr | Development of vaccine formulations: past, present, and future |
title_full_unstemmed | Development of vaccine formulations: past, present, and future |
title_short | Development of vaccine formulations: past, present, and future |
title_sort | development of vaccine formulations: past, present, and future |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889058/ https://www.ncbi.nlm.nih.gov/pubmed/33598818 http://dx.doi.org/10.1007/s13346-021-00924-7 |
work_keys_str_mv | AT damicocarmine developmentofvaccineformulationspastpresentandfuture AT fontanaflavia developmentofvaccineformulationspastpresentandfuture AT chengruoyu developmentofvaccineformulationspastpresentandfuture AT santosheldera developmentofvaccineformulationspastpresentandfuture |